Akari Therapeutics (AKTX) Payables (2011 - 2026)

Akari Therapeutics has disclosed Payables across 16 years of filings, most recently posting $8.7 million for Q1 2026.

• Payables for Q1 2026 came in at $8.7 million, down 34.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.7 million (down 34.64% YoY), and the FY2025 annual result was $8.9 million, down 32.26% from the prior year.
• Payables came in at $8.7 million for Q1 2026 at Akari Therapeutics, down from $8.9 million in the prior quarter.
• In the past five years, Payables ranged from a high of $13.3 million in Q1 2025 to a low of $947000.0 in Q4 2022.
• The 5-year median for Payables is $8.7 million (2026), against an average of $7.5 million.
• Across the five-year window, Payables slumped 47.05% in 2022 and soared 681.93% in 2024, its largest moves.
• Akari Therapeutics' Payables stood at $947000.0 in 2022, then surged by 76.45% to $1.7 million in 2023, then jumped by 681.93% to $13.1 million in 2024, then tumbled by 32.26% to $8.9 million in 2025, then dropped by 1.82% to $8.7 million in 2026.
• The last three Payables figures came in at $8.7 million (Q1 2026), $8.9 million (Q4 2025), and $11.0 million (Q3 2025), per Business Quant data.